MP14-19 SURVIVAL DIFFERENCES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE BASED ON POSITIVE AND NEGATIVE FAMILY HISTORY

Kaifang Ma,Baoan Hong,Haibiao Xie,Kan Gong
DOI: https://doi.org/10.1097/01.ju.0000555315.38462.c7
2019-01-01
Abstract:You have accessJournal of UrologyKidney Cancer: Epidemiology & Evaluation/Staging/Surveillance II (MP14)1 Apr 2019MP14-19 SURVIVAL DIFFERENCES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE BASED ON POSITIVE AND NEGATIVE FAMILY HISTORY Kaifang Ma*, Baoan Hong, Haibiao Xie, and Kan Gong Kaifang Ma*Kaifang Ma* More articles by this author , Baoan HongBaoan Hong More articles by this author , Haibiao XieHaibiao Xie More articles by this author , and Kan GongKan Gong More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000555315.38462.c7AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: Von Hippel-Lindau (VHL) disease is an autosomal-dominant hereditary cancer syndrome occurring in approximately one in 36000 births. Although survival analysis of VHL patients has been described in some studies, the difference between positive family history and negative family history patients remain unclear. We aimed to assess survival differences of patients with VHL disease based on positive and negative family history. METHODS: Patients who diagnosed with VHL disease (n=588) from 216 VHL families were recruited in this retrospective study. We divided patients based on family history: positive family history (PFH) patients (n=507) and negative family history (NFH) patients (n=81). Age-related penetrance of the six major VHL lesions and survival analysis were calculated using Kaplan-Meier plot and Log-rank test. RESULTS: VHL patients with positive family history had lower risks of central nervous system hemangioblastoma (HR=0.55, p=0.0007), renal cell carcinoma (HR=0.28, p<0.0001), pancreatic lesions (HR=0.27, p<0.0001), pheochromocytoma (HR=0.38, p=0.0039), and epididymal or broad ligament cystadenoma (HR=0.23, p=0.0007) than those with negative family history (figure 1). Furthermore, the mean age of first presenting symptom in PFH group was 31.93 years (range 2-74 years), and NFH group was 28.46 years (range 10-54 years). The study also revealed that VHL disease showed high age-associated penetrance in Chinese, the cumulative penetrance by 65 years was about 96.8%. And the median survival for Chinese patients with VHL disease was 61 years (figure 2). CONCLUSIONS: This largest VHL survival analysis manifested that positive family history may be a protective factor of better survival in VHL patients, which is helpful to genetic counselling and clinical decision-making. Source of Funding: the National Natural Science Foundation of China (grant 81572506; 81872081)ï¼›Peking University Health Science Center 985 Action Plan (grant BMU2018WRLJ001) Beijing, China, People's Republic of© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e194-e195 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kaifang Ma* More articles by this author Baoan Hong More articles by this author Haibiao Xie More articles by this author Kan Gong More articles by this author Expand All Advertisement PDF downloadLoading ...
What problem does this paper attempt to address?